Trastuzumab deruxtecan in previously treated HER2‐positive metastatic or unresectable breast cancer: Real‐life data from the temporary use authorization program in …
T Petit, N Hajjaji, EC Antoine, MA Benderra… - Cancer …, 2024 - Wiley Online Library
Background Early access program (formerly cohort Temporary Authorization for Use) was
granted for trastuzumab deruxtecan (T‐DXd) in France based on DESTINY‐Breast01 trial …
granted for trastuzumab deruxtecan (T‐DXd) in France based on DESTINY‐Breast01 trial …
[HTML][HTML] Trastuzumab Deruxtecan in previously treated patients with HER2-positive metastatic breast cancer: updated survival results from a phase II trial (DESTINY …
C Saura, S Modi, I Krop, YH Park, SB Kim, K Tamura… - Annals of …, 2024 - Elsevier
Background Primary analysis of the multicenter, open-label, single-arm, phase II DESTINY-
Breast01 trial (median follow-up 11.1 months) demonstrated durable antitumor activity with …
Breast01 trial (median follow-up 11.1 months) demonstrated durable antitumor activity with …
Trastuzumab deruxtecan for breast cancer: do patients experience a comprehensive benefit?
F Mosele, M Di Maio - Annals of Oncology, 2023 - annalsofoncology.org
Trastuzumab deruxtecan for breast cancer: do patients experience a comprehensive benefit? -
Annals of Oncology Skip to Main Content Advertisement Annals of Oncology European Society …
Annals of Oncology Skip to Main Content Advertisement Annals of Oncology European Society …
Trastuzumab deruxtecan: a review in unresectable or metastatic HER2-positive breast cancer
T Nie, HA Blair - Targeted Oncology, 2023 - Springer
Trastuzumab deruxtecan (Enhertu®) is a human epidermal growth factor receptor 2 (HER2)-
targeted antibody-drug conjugate approved in several countries, including the USA and …
targeted antibody-drug conjugate approved in several countries, including the USA and …
Abstract P2-13-26: Trastuzumab deruxtecan in previously treated HER2-positive metastatic or unresectable breast cancer (BC): First real-life data from the cohort …
T Petit, N Hajjaji, EC Antoine, MA Benderra, M Gozy… - Cancer Research, 2022 - AACR
Abstract Background Trastuzumab deruxtecan (T-DXd) is an antibody-drug conjugate (ADC)
composed of an HER2-directed antibody and a topoisomerase I inhibitor covalently linked …
composed of an HER2-directed antibody and a topoisomerase I inhibitor covalently linked …
A Retrospective Review of the Clinical Outcomes of Trastuzumab Deruxtecan (T-DXd) for the Treatment of Advanced HER2-positive Breast Cancer at the Mount …
M Bienz, A Malek, L Sidon, D Miles - Clinical Oncology, 2023 - clinicaloncologyonline.net
Purpose: Trastuzumab deruxtecan (T-DXd) has been available since April 2021 via the
Cancer Drugs Fund for patients with unresectable or metastatic HER2-positive breast cancer …
Cancer Drugs Fund for patients with unresectable or metastatic HER2-positive breast cancer …
191P Use and outcomes of trastuzumab deruxtecan in HER2-positive and HER2-low metastatic breast cancer in real-world setting: A nationwide cohort study
N Haddy, H Jourdain, D Desplas, I Mansouri… - ESMO Open, 2024 - esmoopen.com
Background Since 2020, trastuzumab deruxtecan (T-DXd) has been used in France for
patients with previously treated HER2-positive or HER2-low metastatic breast cancer (mBC) …
patients with previously treated HER2-positive or HER2-low metastatic breast cancer (mBC) …
Safety of trastuzumab deruxtecan and radiation therapy combination in HER2-positive metastatic breast cancer patients
L Visani, I Ratosa, D Ribnikar, C Becherini… - European Journal of …, 2024 - ejcancer.com
Background: Trastuzumab deruxtecan (T-DXd) currently represents the standard of care for
the treatment of patients with metastatic HER2-positive (HER2+) breast cancer (BC) after …
the treatment of patients with metastatic HER2-positive (HER2+) breast cancer (BC) after …
Real-life experience of trastuzumab deruxtecan (T-DXd) in patients with heavily pretreated HER2 positive advanced breast cancer: A retrospective single institution …
E Vosoughi, N Nafissi, A Mahadevan, S Lee, K Parajuli… - 2023 - ascopubs.org
e13035 Background: T-DXd is a HER2 antibody–drug conjugate. It improves patient
outcomes and is FDA approved for the treatment of patients with Her-2 positive and Her-2 …
outcomes and is FDA approved for the treatment of patients with Her-2 positive and Her-2 …
Mechanism of action and resistance to trastuzumab deruxtecan in patients with metastatic breast cancer: the DAISY trial
Trastuzumab deruxtecan (T-DXd) is an anti-HER2 (human epidermal growth factor receptor
2) antibody-drug conjugate which has previously shown efficacy in patients with HER2 …
2) antibody-drug conjugate which has previously shown efficacy in patients with HER2 …